Special Issue
Topic: Lung Cancer Drug Resistance
Guest Editor(s)
Prof. Shi-Yong Sun
Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.
Special Issue Introduction
The field of lung cancer is changing rapidly, and the treatment options are becoming increasingly rich. Beyond the classic treatment options, such as surgery, radiotherapy and chemotherapy, targeted therapy and immunotherapy have played important roles in the treatment of lung cancer. There has been an increase in the number of drug targets identified for lung cancer. A new generation of targeted drugs have emerged one after another. The treatment port even moves forward to early stage. Immunotherapy combined with chemotherapy has become a new clinical practice. We are looking forward to the emergence of these new treatment models. However, drug resistance is always the bottleneck to preventing drugs or new regimens from playing a further role. This Special Issue pays special attention to drug resistance in the treatment of lung cancer. We hope that through this issue, we can have a deep understanding of the existing problems, the underlying mechanism and the future solutions, and hope that the publication of this Special Issue can bring some inspiration to readers. We warmly welcome the contributions of the clinical and basic translational experts engaged in this research field and interested in this Special Issue. This Special Issue will discuss the problems and the direction and space of scientific research in the future.
Submission Deadline
20 Sep 2021
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=648
Submission Deadline: 20 Sep 2021
Contacts: Bella Zhao, Assistant Editor, bella@cdrjournal.com
Published Articles
Emerging insights to lung cancer drug resistance
Open Access Editorial 20 Jun 2022
DOI: 10.20517/cdr.2022.61
Views: Downloads:
Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancer
Open Access Original Article 24 Mar 2022
Views: Downloads:
Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer
Open Access Review 7 Feb 2022
Views: Downloads:
Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
Open Access Review 7 Feb 2022
Views: Downloads:
Views: Downloads:
Tumor-derived exosomes: immune properties and clinical application in lung cancer
Open Access Review 7 Feb 2022
DOI: 10.20517/cdr.2021.99
Views: Downloads:
Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
Open Access Original Article 3 Jan 2022
DOI: 10.20517/cdr.2021.85
Views: Downloads:
Shenmai injection enhances cisplatin-induced apoptosis through regulation of Mfn2-dependent mitochondrial dynamics in lung adenocarcinoma A549/DDP cells
Open Access Original Article 9 Dec 2021
DOI: 10.20517/cdr.2021.94
Views: Downloads:
EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature
Open Access Case Report 30 Nov 2021
DOI: 10.20517/cdr.2021.98
Views: Downloads:
Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer
Open Access Original Article 23 May 2021
DOI: 10.20517/cdr.2021.28
Views: Downloads: